Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis

Tej K. Pareek1, Abdelmadjid Belkadi2, Sashi Kesavapany3, Anita Zaremba2, Sook L. Loh2, Lianhua Bai2, Mark L. Cohen4, Colin Meyer5, Karen T. Liby6, Robert H. Miller2, Michael B. Sporn6 & John J. Letterio1

1Department of Pediatrics/Division of Pediatric Hematology-Oncology, University Hospitals Case Medical Center and The Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH44106, 2Centers for Stem Cells and Regenerative Medicine, Translational Neuroscience, Department of Neurosciences, Case Western Reserve University, School of Medicine, Ohio 44106, Cleveland, 3Department of Biochemistry, Neurobiology Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, 4Department of Pathology, Case Western Reserve University, OH 44106, 5Reata Pharmaceuticals Inc., Irving, TX 75063, 6Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755.

Inflammatory cytokines and endogenous anti-oxidants are variables affecting disease progression in multiple sclerosis (MS). Here we demonstrate the dual capacity of triterpenoids to simultaneously repress production of IL-17 and other pro-inflammatory mediators while exerting neuroprotective effects directly through Nrf2-dependent induction of anti-oxidant genes. Derivatives of the natural triterpene oleanolic acid, namely CDDO-trifluoroethyl-amide (CDDO-TFEA), completely suppressed disease in a murine model of MS, experimental autoimmune encephalomyelitis (EAE), by inhibiting Th1 and Th17 mRNA and cytokine production. Encephalitogenic T cells recovered from treated mice were hypo-responsive to myelin antigen and failed to adoptively transfer the disease. Microarray analyses showed significant suppression of pro-inflammatory transcripts with concomitant induction of anti-inflammatory genes including Ptgds and Hsd11b1. Finally, triterpenoids induced oligodendrocyte maturation in vitro and enhanced myelin repair in an LPC-induced non-inflammatory model of demyelination in vivo. These results demonstrate the unique potential of triterpenoid derivatives for the treatment of neuroinflammatory disorders such as MS.

The dynamic regulation of cytoprotective genes in response to inflammatory mediators contributes to the relapsing-remitting nature of multiple sclerosis (MS). In murine models of MS, initiation of disease requires induction of a Th17 T cell response with disease manifestations ultimately resulting from activated macrophages which phagocyte myelin and contribute to degeneration of myelin sheaths, oligodendrocytes and axons. Activated monocytes and macrophages produce inflammatory mediators, including nitric oxide and reactive oxygen species (ROS), which contribute to the development and progression of the disease. Generation of ROS in brain parenchyma contributes to lesion persistence by mediating oligodendroglial damage and axonal injury, and reduced serum levels of antioxidants have been observed in patients with MS.

The central nervous system is endowed with several protective mechanisms consisting of enzymatic and non-enzymatic antioxidants whose expression is regulated through the transcription factor nuclear factor-E2-related factor (Nrf2) and the antioxidant response element (ARE). In humans with MS, enhanced expression of Nrf2/ARE-regulated antioxidants in the brain is indicative of the response to oxidative stress, and in mice disruption of Nrf2 gene expression (Nrf2−/− mice) leads to exacerbation of clinical and pathological symptoms of experimental autoimmune encephalomyelitis (EAE). Nrf2−/− mice are also hypersensitive to LPS-induced neuroinflammation and Nrf2 is reported to be involved in maintaining CNS myelin. To date, over 200 Nrf2/ARE-driven genes involved in detoxification and antioxidant defense have been identified, out of which superoxide dismutases (SOD), glutathione peroxidases, GPxs, catalases, and hemeoxygenases-1 (Hmox-1) are all modulated during MS.
The families of natural and synthetic triterpenoids have recently emerged as potent regulators of the Nrf2/ARE pathway. Triterpenoids represent a broad category of molecules ubiquitously present in the plant kingdom\textsuperscript{16,17}, and used widely in Asian medicine (usually in the form of herbal extracts)\textsuperscript{18}. Among these natural triterpenoids, the natural pentacyclic triterpene oleanolic acid (OA) displays numerous biological properties with therapeutic potential\textsuperscript{19,20}. Both OA and herbal extracts containing OA are known for their immunomodulatory properties\textsuperscript{21} and have been shown to reduce clinical pathology associated with neuroinflammation and EAE\textsuperscript{22,23}.

Oleanolic acid has served as the platform for synthesis of several novel triterpenoids, including 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me) which is currently in Phase III clinical trials in patients with diabetic nephropathy\textsuperscript{23,24}. In preclinical studies, CDDO-methyl amide (CDDO-MA) was shown to exert neuroprotective effects through potent activation of the Nrf2/ARE pathway and is neuroprotective in preclinical model systems, including a transgenic model of Alzheimer’s disease\textsuperscript{25}. Further derivatization of CDDO to yield an imidazolide (CDDO-Im), an ethyl amide, (CDDO-EA), or a trifluoroethyl amide (CDDO-TFEA), resulted in significantly increased biological activity\textsuperscript{26}, and enhanced capacity to cross the blood brain barrier (BBB)\textsuperscript{27}.

In this study we reveal the mechanisms mediating neuroprotective effects of three CDDO derivatives CDDO-Me, CDDO-EA and CDDO-TFEA in the treatment of EAE. Daily systemic administration of these compounds alone significantly alleviates the clinical symptoms of disease. We show that CDDO-TFEA not only induces Nrf2 expression and signaling both in affected CNS tissue as well as in peripheral lymphocytes, but also leads to global suppression of inflammatory response genes in mice with EAE and suppression of disease associated cytokines, particularly interleukin-17 (IL-17). Lastly, CDDO-TFEA protects against non-inflammatory lysophosphatidyl choline (LPC)-induced demyelination suggesting a direct action of this molecule on myelin preservation and repair. These results reveal the potency and unique mechanisms through which novel synthetic triterpenoids, specifically CDDO derivatives, suppress disease progression in the setting of inflammatory neurodegenerative disease.

### Results

**CDDO derivatives promote complete resolution of EAE.** To investigate the efficacy of selected synthetic triterpenoids (Fig. 1A), mice were immunized with either MOG 35–55 (C57BL/6 mice) or PLP (139–151) (Balb/C mice) and received systemic administration of either CDDO-Me, CDDO-EA, or CDDO-TFEA after the onset of disease. Administration of triterpenoids every alternate day for 10 days significantly improved survival (Fig 1B) and led to complete abrogation of clinical symptoms within the first two weeks of treatment, regardless of disease score at the onset of treatment (Fig. 1 C). Recrudescence of disease symptoms was significantly delayed after treatment with CDDO-TFEA, when compared to CDDO-Me (Fig. S1-A) and CDDO-EA (Fig. S1-B). Re-exposure of these mice to the same molecule resulted in complete suppression of clinical symptoms in all treatment groups. The severity of symptoms at disease relapse was low and survival was greater than 90% for mice treated with either the ethyl-amide or trifluoroethylamide derivatives. The beneficial effects of CDDO-TFEA were reproducible in the remitting relapsing model of PLP (139–151)-induced EAE (Fig. 1D). The effect of these small molecules on EAE disease progression may involve a combination of suppressive activity on the peripheral immune system and direct neuroprotective effects in the CNS. The former is supported by our observation that lymphocytes collected from mice immunized with MOG (35–55) and subsequently exposed to CDDO-TFEA completely failed to adoptively transfer disease to untreated mice (Fig. S2).

**CDDO-TFEA attenuates CNS inflammation and demyelination in mice with EAE.** To assess the effects of CDDO-TFEA and other derivatives on EAE-associated CNS pathology, lumbar spinal cord and brain stem were obtained from mice either at the peak of disease

![Figure 1](http://www.nature.com/scientificreports/)  
**Figure 1 | Systemic administration of CDDO derivatives ameliorates the severity of EAE.** (A) Chemical structure of the parent molecule, CDDO, and its derivatives used in this study. (B) Survival of mice was recorded (Kaplan-Meier survival curve) within 3 months of MOG (35–55) immunization. (C) C57BL/6 mice were pooled at different clinical scores and CDDO-TFEA was administered by i.p. injections (as described in methods section) on alternate days at the indicated time points; a specific clinical score was assigned to each mouse at 48 hr intervals and these scores are depicted as mean clinical scores. (D) SJL mice were immunized with PLP (139–151) and treated with CDDO-TFEA on alternate days during the indicated time points. All data are presented as the mean ± S.E.M. (n = 10–12 mice in each group).
severity or at a point when disease scores approached baseline. Independent histological analysis of brain stem (Fig. S3) and spinal cord demonstrated reduced inflammation (Fig. 2A–C & 2M) and minimal demyelination (Fig. 2D–F & 2N), in CDDO-TFEA-treated animals when compared with the untreated control group. There was a significant reduction in the number of F4/80 (macrophage and microglia; Fig. 2G–I) and myeloperoxidase (neutrophil, Fig. 2J–L) positive cells in the lumbar spinal cord of mice treated with CDDO-TFEA. These data support a conclusion that suppression of immune and inflammatory cell populations is one mechanism underlying the response to synthetic triterpenoids in EAE.

**Treatment with CDDO-TFEA diminishes inflammatory cytokine levels.** Our laboratory and others have shown direct suppressive effects of triterpenoids on immune cell activation and on receptor-mediated activation of signaling intermediates including Stat3 and NFκB28,29. To determine whether triterpenoid suppression of CNS infiltration by immune cells in mice with EAE was linked to suppression of the immune response in the periphery, we first analyzed serum and supernatants of cultured peripheral blood lymphocytes harvested from mice with EAE and re-stimulated ex vivo in the presence or absence of CDDO-TFEA (Fig. 3A–G). A significant reduction in Th1 and Th17 cytokines (i.e. IL6, IL17, IFNγ, TNFα and GMCSF) was observed while IL-2 production was not altered significantly. Lymphocytes collected from spleen and inguinal lymph nodes of mice 21 days after MOG (35–55) injection secreted several cytokines when restimulated with MOG (35–55) peptide ex vivo, but production of IL2, IL4, IL6, IL17, TNF-α, IFN-γ and GMCSF was significantly lower in lymphocytes harvested from mice treated with CDDO-TFEA. When these data were normalized for cell proliferation (to account for effects of CDDO-TFEA on cell growth) the differences in IL17 and GMCSF production remained highly significant.

CDDO-TFEA suppresses antigen-specific lymphocyte responses and modulates Hmox-1 and iNOS protein expression. The data presented thus far suggest that triterpenoids may suppress EAE through direct effects on immune cell activation and function. We hypothesized that CDDO-TFEA might impair development of an antigen-specific memory response to MOG (35–55) through direct suppression of T cell activation or cytokine driven proliferative expansion. Here we show that CDDO-TFEA treatment significantly inhibited the responses to CD3/CD28 and IL7 both alone and in combination (Fig. S4). Interleukin-7 (IL7) is a non-redundant cytokine essential for T cell survival and development and T cell memory30. Patients suffering with MS have a higher level of IL7 and IL7R-alpha in the cerebrospinal fluid compared with patients suffering from other non-inflammatory neurological disorders31. CDDO-TFEA significantly suppressed IL-7 stimulated in vitro proliferation of both quiescent and activated T cells isolated from spleen and lymph nodes of mice immunized with MOG (Fig. S4). We assessed the ex vivo responsiveness of lymphocytes isolated from lymph nodes and spleen of either a) control mice, b) MOG(35–55)-immunized mice with symptoms of EAE or c) MOG(35–55)-immunized mice following treatment with CDDO-TFEA. Lymphocytes derived from lymph nodes of symptomatic mice restimulated with MOG (35–55) in vitro had a more than 5-fold greater proliferative response relative to control lymphocytes, but this response was significantly diminished in cultures of lymphocytes isolated from mice treated with CDDO-TFEA in vivo. In either case, the in vitro treatment of these cells with CDDO-TFEA completely blocked proliferation in response to MOG (35–55) (Fig. 4A). These data demonstrate a direct suppression of the lymphocyte proliferative response to antigen and IL7 stimulation by CDDO-TFEA and related triterpenoids.

Triterpenoids have also been shown to control inflammation by suppressing expression of inducible nitric oxide synthase (iNOS) in

---

**Figure 2 | Decreased inflammation and preservation of myelin content after CDDO-TFEA treatment.** Mice were sacrificed after MOG (35–55) immunization either at the peak of clinical symptoms or at a clinical score of zero and after respective treatments with either vehicle control or CDDO-TFEA and CNS tissues were subjected to histopathological analysis. Representative sections of lumbar spinal cord (A–L) from control mice with clinical signs of EAE or from mice treated with CDDO-TFEA were stained with hematoxilin and eosin to assess inflammation (A–C), with Luxol fast blue to assess myelin (D–F & 2N), in CDDO-TFEA-treated animals when compared with the untreated control group. There was a significant reduction in the number of F4/80 (G–I) and myeloperoxidase (neutrophil, J–L) positive cells in the lumbar spinal cord of mice treated with CDDO-TFEA. These data support a conclusion that suppression of immune and inflammatory cell populations is one mechanism underlying the response to synthetic triterpenoids in EAE.
Figure 3 | CDDO-TFEA treatment suppressed production of key inflammatory cytokines by lymphocytes during EAE. Serum was collected from mice, including controls, mice with EAE (at clinical score 5) and mice with EAE following treatment with CDDO-derivatives both at the peak of disease severity and after they reached a clinical score 0. Production of cytokines from peripheral lymphocytes obtained from these mice was determined after culturing them for 72 hrs ex vivo. ELISA was performed to detect cytokine levels of IL-2 (A), IL-4 (B), IL-6 (C), IL-17 (D), IFNγ (E), TNF-α (F) and GMCSF (G). All data are presented as the mean ± SEM (n = 6). **, P < 0.01, *, P < 0.05, Student’s t test.

Figure 4 | CDDO-TFEA inhibits lymphocyte proliferation and modulates iNOS and Hmox-1 protein expression in the CNS of affected mice. (A) Lymphocytes were collected from control mice, mice with EAE (at clinical score 5) or from mice with EAE following treatment with CDDO-TFEA (at clinical score 0) and cultured for 72 hrs in the presence or absence of MOG (35–55), with or without CDDO-TFEA. During last 16 hrs, 3H-thymidine was added to cultures and the incorporated amount of 3H-thymidine in cells was measured as CPM. Protein lysates were prepared from lumbar spinal cord (B) and brain stem (C) of control mice, mice with EAE (at clinical score 5) or mice with EAE following CDDO-TFEA treatment (at clinical score 0) and subjected to Western blot analysis to check iNOS and Hmox-1 protein levels. Equal loading of samples was confirmed by actin immunodetection. Data is presented as the mean ± SEM (n = 6). ***, P < 0.001, **, P < 0.01, Student’s t test.
Macrophages. CNS levels of iNOS increase over the course of EAE32-35, resulting in prolonged exposure to nitric oxide36 which is cytotoxic37 and promotes inflammation38. We found elevated levels of iNOS present in the lumbar spinal cord (Fig. 4B) and brain stem (Fig. 4C) of mice with EAE that were reduced significantly after CDDO-TFEA treatment. When the same tissues were evaluated for the expression of Hmox-1, we observed a reciprocal relationship. Prior reports have shown a link between hemin-induced Hmox-1 expression and reduced clinical severity of EAE in rats, whereas tin mesoporphyrin, a well-known inhibitor of Hmox-1 markedly exacerbated EAE39. Moreover, induction of EAE in Hmox1-/- mice led to enhanced CNS demyelination, paralysis, and mortality39. The significant up-regulation of Hmox-1 protein in brain stem and lumbar spinal cord after CDDO-TFEA treatment suggests a possible mechanism through which this small molecule may be exerting neuroprotective effects in EAE.

Concomitant regulation of Nrf2-dependent and inflammatory gene transcription. The observed induction of Hmox-1 protein in CNS tissues following CDDO-TFEA exposure is consistent with the ability of the triterpenoids to activate Nrf2-dependent expression of the Hmox-1 gene. We used real-time PCR to evaluate the expression of Hmox-1 and several inflammation-related genes (including IFN-γ, IL-17 and iNOS) in total CNS tissue (Fig. 5A–B) and in splenocytes (Fig. 5C) and in mononuclear cells isolated from the CNS (Fig. 5D) of mice with EAE. A significant increase in Nrf2 and Hmox-1 transcripts was detected in lymphocytes of mice treated with CDDO-TFEA during the course of disease (Fig. 5A–C), and in mononuclear cells isolated from the CNS (Fig. 5D). Moreover, CDDO-TFEA significantly induced Nrf2 and Hmox-1 gene expression by encephalitogenic splenocytes cultured in the presence of MOG (35–55) (Fig. 5C).

The pathogenic role of IL-17 in EAE has been substantiated by studies in mice deficient in IL-17 or the IL-17-inducing cytokine IL-2340. We observed complete suppression of IFN-γ and IL-17 gene expression in total CNS tissue (Fig. 5A–B) as well as in mononuclear cells isolated from brain stem and lumbar spinal cord (Fig. 5D) after CDDO-TFEA treatment. Moreover, CDDO-TFEA significantly reduced both IFN-γ and IL-17 expression by lymphocytes isolated from mice immunized with MOG (35–55), when these cells were re-exposed to MOG (35–55) in vitro (Fig. 5C). Collectively, these data highlight the multifunctional nature of the synthetic triterpenoids and the central role of Nrf2-mediated induction of pathways that combat oxidative stress, including the Hmox-1 pathway. The data also suggest the observed triterpenoid effect involves regulation of immune cells both at the site of disease and in the periphery.

CDDO-TFEA suppresses non-inflammatory LPC-induced demyelination. The data presented thus far suggests that neuronal integrity is maintained by CDDO-TFEA during EAE induction. However, the question remains whether this effect of CDDO-TFEA is solely due to immune suppression or whether triterpenoids also exert direct effects on myelin stability or regeneration. To address this question we utilized the well-established non-inflammatory lysophosphatidyl choline (LPC)-induced rodent model of myelin injury. Direct injection of LPC into neural tissue produces a localized vesicular demyelination of neurons that spares axons40. In the LPC-induced demyelination paradigm, a small amount of exogenous LPC injected into the dorsal columns of the thoracic spinal cord activates membrane bound phospholipase-A2, which then hydrolyzes the lecithin of myelin leading to membrane solubilization and demyelination with fully developed lesions at 2 days post-injection41. To test the efficacy of CDDO-TFEA on LPC-induced de-myelination, a total of 12 rats were subjected to LPC injection within dorsal column of spinal cord; 6 of these also received 10 nM CDDO-TFEA with LPC injection and then again at the site of injury 48 hours after LPC injection. Tissues were removed 7 days following injury and processed for immunostaining with anti-MBP antibody (for myelin), anti-GFAP antibody (for astrocytes) and anti-NG2 antibody (for oligodendrocytes).

Control mice (injected with PBS) exhibit intact myelin and a normal distribution of astrocytes (Fig. 6A–D) and oligodendrocytes (Fig. S5A–D). However, at the site of LPC injection neurons were completely demyelinated (Fig. 6G & Fig. S4G), astrocytes formed a glial scar around the demyelinated area (Fig. 6F and 6H) and oligodendrocytes were recruited around demyelinated axons (Fig. SSF and SSH).

---

Figure 5 | CDDO-TFEA treatment modulates both antioxidant and inflammatory gene transcription in the CNS and in peripheral lymphocytes. Data represent the fold increase in gene expression levels as detected by quantitative PCR performed on mRNA collected from either (A–B) total CNS tissue, (C) peripheral lymphocytes or (D) mononuclear cells collected from the CNS tissues of control mice or from those with EAE (at the peak of the disease) or from mice with EAE following treatment with CDDO-TFEA (when clinical scores returned to baseline). All data are the mean ± SEM. **, P < 0.01, Student’s t test.
Myelin was significantly protected in the CDDO-TFEA treated group (Fig. 6K and Fig. S5K), with a comparatively normal distribution of astrocytes and oligodendrocytes. These data were further confirmed by toluidene blue staining and electron microscopy (Fig. 6M–R). We observed completely naked axons at the site of LPC injection (Fig. 6N & 6Q) while administration of CDDO-TFEA preserved myelin at the site of LPC injection (Fig. 6O and 6R), as defined by the percentage of myelinated axons and their G ratios in the dorsal horn of the spinal cord at the site of LPC injection (Fig. 6S–T).

The data above indicate that CDDO-TFEA promotes preservation of myelin at the site of injury, but it is also possible that CDDO-TFEA may additionally promote myelin repair by facilitating oligodendrocyte maturation. To address this question, oligodendrocytes harvested from the CNS of day E18 rat embryos and were cultured for 10 days in either the presence or absence of CDDO-TFEA. CDDO-TFEA significantly enhanced maturation of oligodendrocyte precursors as shown by expression of maturation markers A2B5 (Fig. 7A–F & 7M) and O4 (Fig. 7G–L & 7N). These data indicate that during EAE, CDDO-TFEA and related synthetic triterpenoids act as multifunctional agents, both suppressing the immune response while also acting directly on neurons to protect them from the demyelination process and to promote myelin repair.

A unique triterpenoid-modulated transcriptome underlies the resolution of EAE. To better characterize the triterpenoid modulated transcriptome in EAE we performed a gene microarray.
(Illumina Sentrix array Ref. 8v1.1) on lumbar spinal cord, directly comparing tissues collected from control mice and from mice following induction of EAE, with or without exposure to CDDO-TFEA. A total of 1433 genes were found to be differentially modulated in mice at the peak of EAE clinical scores compared to control mice (Fig. 8A). Among them, 135 genes known to be involved either in the cellular stress response or in inflammation were significantly altered by CDDO-TFEA treatment, and in most instances their expression returned to baseline (Fig. 8B–D). However, the induction of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and of prostaglandin D2 synthase (PGDS) suggests that activation of steroid and prostaglandin biosynthetic pathways may contribute to the suppression of CNS inflammation by triterpenoids. We validated these gene array results by performing real time PCR on 9 different genes (Fig. 8E). The data suggest that inflammation driven suppression of both 11βHSD1 and of PGDS is reversed by exposure to CDDO-TFEA.

Discussion

Multiple mechanisms operant in MS culminate ultimately in the generation of a highly oxidative microenvironment that is responsible for tissue injury and neurodegeneration. The data presented here add to a growing body of literature that strongly support the clinical development of the family of natural and synthetic triterpenoids as chemopreventive and therapeutic agents in the context of neuro-inflammatory and neurodegenerative diseases, and specifically in the context of MS. While neuroprotective effects of administered exogenous antioxidants have been reported in EAE, pursuit of strategies that employ newer agents such as synthetic triterpenoids to induce endogenous enzymatic antioxidants should confer more efficient means to inhibit the detrimental effects of ROS and thereby serve as an effective form of chemoprevention for MS.

Synthetic oleanane triterpenoids have emerged as a potent class of pharmacologic agents capable of strongly inducing the Nrf2-ARE axis, and this mechanism has been identified as playing a principal role in the neuroprotective effects of CDDO derivatives in a variety of models of neurodegenerative disorders. For example, in the murine SOD-1 model of Amyotrophic Lateral Sclerosis (ALS), exposure to CDDO-EA and CDDO-TFEA results in nuclear translocation of Nrf2 in cells expressing the SOD-1 mutant, and suppressed disease progression whether treatment was initiated in asymptomatic mice or at the onset of clinical manifestations. While the clinical response observed in the EAE model may be attributed to effects on Nrf2 expression and function, triterpenoids are multifunctional agents and it is quite likely that multiple targets participate in conferring protection in the setting of a complex neurodegenerative process like MS. For example, a role for Stat3 not only in the genesis of Th17 cells but also in the development of EAE has been defined. Our laboratory and others have shown that Stat3 is a direct target of the synthetic triterpenoids. Our demonstration that triterpenoid exposure following induction of EAE significantly represses both IL-17 mRNA and protein expression suggests that this mechanism may also contribute to the overall clinical response to triterpenoids in the EAE model.

It is noteworthy that the link between an induction of Hmox-1 and repression of the development of a Th17 response has also been demonstrated for other activators of Hmox-1 in preclinical models of EAE and inflammatory bowel disease (IBD). Hemin, a potent inducer of Hmox-1 and activator of Nrf2, suppresses the development of IBD in mice exposed to dextran sodium sulfate (DSS) and this effect is also associated with a significant reduction in the production of IL-17. Similarly, intraperitoneal administration of erythropoietin to MOG-EAE mice significantly reduced severity of disease in a manner that correlated with potent upregulation of Hmox-1 in the CNS and spleen and with a reduction of Th-17 T cell subsets. Finally, the observation that IL-17 might act to directly suppress the expression of Hmox-1 in the context of an inflammatory response argues that the balance between these two factors may in fact be an important determinant of disease expression. Thus the unique capacity of triterpenoids to simultaneously repress IL-17...
Figure 8 | Microarray analysis of CNS tissues reveals global suppression of inflammatory genes by CDDO-TFEA in mice with EAE, with a concomitant induction of genes linked to resolution of inflammation. Gene microarray analysis using Illumina Sentrix array Ref. 8v1.1, using mRNA collected from lumbar spinal cord of control mice and mice with EAE treated either with vehicle control or with CDDO-TFEA. (A) Heat map of 1433 genes differentially expressed in EAE mice compared to control mice. (B) Heatmap of 135 genes significantly altered by CDDO-TFEA treatment. (C) Magnified heat map (from panel B) of genes either down-regulated during EAE or (D) up-regulated during EAE, and their return to baseline after CDDO-TFEA treatment. (E) Quantitative PCR was performed using selected probes (as described in material method section) and RNA collected from affected CNS tissue of mice induced to develop EAE and treated with either CDDO-TFEA or vehicle control. β-actin levels were tested to normalize the amount of RNA and relative fold induction of transcript was calculated by comparing the basal level of expression of selected genes in normal mouse tissues. All data are the mean ± SEM. **, P < 0.01, Student’s t test.
expression through inhibition of Stat3 and to activate HO-1 through inhibition of Stat3 and to activate HO-1 through expression of the endogenous anti-oxidant response and raising the question whether the observed clinical response to triterpenoids shown here might reflect their capacity to mimic many of the functions of this endogenous anti-inflammatory protein.

Lastly, our data in the model of LPC-induced demyelination suggest that the efficacy of triterpenoids in the context of EAE is linked to a capacity to regulate astrocyte activation and to preserve CNS myelin. Nrf-2/- mice develop a spontaneous progressive leukoencephalopathy, with vacuolar degeneration that is linked to myelin unwinding, intramyelinic cysts and oxidative damage to myelin. Similarly, the observation that the anti-oxidant fumaric acid (FA) can preserve myelin and axonal density has also been linked to the capacity of FA and its esters to regulate Nrf-2 activity, and may be a mechanism contributing to the observed reduction of gadolinium enhancing lesions in MS patients treated with dimethylfumarate.

Indeed, the beneficial effects of dimethylfumarate for axon preservation and astrocyte activation in the MOG-EAE model are lost in mice deficient in Nrf-2 gene expression.

In conclusion, the data present here demonstrate the efficacy of multifunctional triterpenoids in suppressing clinical and pathologic features of disease in preclinical models of MS. These small molecules have a unique capacity to simultaneously target intermediates that drive production of disease-inducing cytokines, such as IL-17, while inducing neuroprotective pathways activated through Nrf-2. Thus, synthetic triterpenoids may serve as both therapeutic and chemopreventive agents in the context of neurodegenerative and inflammatory diseases affecting the CNS.

Methods

Animals. C57BL/6 and SJL female mice (for EAE studies) and male Wistar rats (for LPC studies) were housed in a pathogen free animal facility in standard cages with free access to food and water in climate and light controlled rooms. All experimental procedures were approved by the Animal Care and Use Committee of the Case Western Reserve University.

EAE induction. EAE was induced in 10–12 weeks old, age matched female mice by subcutaneous immunization on both flanks with 200 μl of emulsion containing either Complete Freund’s adjuvant (100 μl of incomplete Freund’s adjuvant with 8 mg/ml of Mycobacterium Tuberculosis and 100 μl of PBS) (DIFCO Laboratories) or Complete Freund’s adjuvant with 200 μg of MOG (35–55). At the time of injection and 48 hours later 200 ng of pertussis toxin (List Biological Laboratories) was injected intraperitoneally in 100 μl of PBS. Mice were monitored for daily clinical signs of EAE and the following criteria were used to grade clinical scores: 0: no signs of disease; 1-limp tail; 2-moderate hind-limb weakness; 3-severe hind-limb weakness; 4-Complete hind limb paralysis; 5- quadriplegia or premonibund state; 6-death.

Drug treatment. CDDO-Me, CDDO-EA or CDDO-TFEA were dissolved in a minimal amount of DMSO to obtain 10 mM stock and further dissolved in 7.5% PBST (7.5 ml Tween-80 dissolved in 100 ml of PBS) to obtain a final concentration of 100 nM. Animals were injected with 100 μl of this solution by intra-peritoneal (i.p.) injection at the interval of 48 hours for a total of 5 injections. Therapy was initiated in mice with varying severity of disease as noted by different clinical scores, starting after 15 days of MOG-35-55 immunization. Control animals were injected with a similar volume of vehicle i.e. 7.5% PBST.

Histology and immunohistochemistry. On day 18 to 23 (at clinical scores 4 to 5 in control mice with EAE) and at clinical score 0 in recipients of CDDO-TFEA treatment, mice were anesthetized and perfused with phosphate buffer saline (PBS) followed by 4% paraformaldehyde in PBS (PFA-PBS). Brain and spinal cord were collected for embedding in 4% PFA in parallel to obtain 5 μm thick sections. At least 10 to 12 serial sections were obtained from 4 different regions of the brain (rostral cerebrum, mid cerebrum, mid brain and cerebellum with brain stem). Spinal cord was divided into 3 parts (cervical, thoracic and lumbar). At least 5 sections from each part and longitudinal serial sections of all regions were obtained for representation of the entire spinal cord. Tissue sections were stained with hematoxilin & eosin (H&E) to assess routine histology and inflammation and also with Luxol Fast Blue and the Periodic Acid Schiff reagent to analyze myelin content. Each section was assigned a histological score for inflammation and demyelination from 0 to 3 by an observer blinded to sample identity, where 0 represents no lesions, 1-moderate lesions and 3 represents severe lesions. Spinal cord sections were immunostained with anti myeloperoxidase antibody to detect granulocytes infiltration and anti-F4/80 antibody for macrophage and microglia.

Western blot analysis. Animals were sacrificed for tissue collection at different time points after immunization and drug treatment. Brain (further divided into forebrain, midbrain and hindbrain) and spinal cord (further divided into cervical, thoracic and lumbar) were collected and snap frozen. Tissue homogenates were prepared in lysis buffer, consisting of T-PER, tissue protein extraction reagent (Pierce, Rockford, IL), a protease inhibitor cocktail tablet (Roche, Mannheim, Germany) and 1:100 diluted phosphatase inhibitor mixtures I and II (Sigma, St. Louis, MO). Proteins were denatured and equal amounts of proteins were electrophoresed in 4–12% bis-Tris/ polyacrylamide gels (NuPAGE; Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes with 0.2 μm pores (Invitrogen). The membranes were blocked for 2 h in blocking solution (TBS containing 10% nonfat dry milk and 0.05% Tween 20) and incubated overnight at 4 °C with primary antibody diluted in blocking solution. Incubation with horseradish peroxidase-conjugated secondary antibody was performed at room temperature for 1 h, and immunoreactivity was detected by using enhanced chemiluminescence (Pierce, Rockford, IL).

Oligodendrocyte primary culture. Dissociated brain cultures were made from Sprague-Dawley rat pups at postnatal day 3, plated on poly-l-lysine/Laminin coated coverslips and grown in 1% fetal bovine serum in DMEM supplemented with Glutamax and Penicillin-Streptomycin. A2B5+ (indicative of oligodendrocyte precursor cells), and O4, (for mature marker of oligodendrocyte secondary antibody) was performed at room temperature for 1 h, and immunoreactivity was detected by using enhanced chemiluminescence (Pierce, Rockford, IL).

Antibodies. The rabbit polyclonal anti-iNOS and anti-Hmox-1 (Santa Cruz Biotechnology,Santa Cruz, CA) were used for Western blot analysis (1:200). For immunohistochemistry 2μg/ml of rabbit polyclonal anti-myeloperoxidase (lot 373/A663A (1)); Lab Vision; Fremont, CA), or 10 μg/ml of the rat IgG2b MAb F4/80 (clone C1:A3-1; Serotec; Raleigh, NC) were used. Secondary horseradish-peroxidase-conjugated antibodies were obtained from AmershamBiosciences (Piscataway, NJ) and used at 1: 2000 dilution for immunoblots analysis and 2.5 μg/ml biotinylated rabbit anti-rat IgG secondary antibody (Vector Laboratories; Burlingame, CA) to detect F4/80 and 2.5 μg/ml biotinylated goat anti-rabbit IgG secondary antibody (Vector) to detect myeloperoxidase.

ELISA. Serum levels of IL-2, IL-4, IL-6, GM-CSF, TNF and IFN-γ were detected with OptEIARa ELISA kits (BD Biosciences and IL-17 was detected with DuoSet ELISA development System (R&D systems) as per manufacturer’s suggested protocol.

Ex vivo restimulation of T cells. Mice immunized with or without MOG(35-55) (clinical score-5) or CDDO-TFEA treated (clinical score-0) were sacrificed and a single cell suspension was prepared from draining lymph nodes (Inguinal and brachial) and restimulated with 35 μg/ml of MOG (35–55) in presence or absence of CDDO-TFEA. Cells and 50 μg/ml of 3H thymidine was added in cultures during last 12 hours and thymidine incorporation was measured as cell proliferation.
LPC induced demyelination. Three to four months old male Wistar rats were used for this study. Demyelination in the spinal cord was induced by LPC injection as described previously23 with slight modification in protocol. In brief, animals were anesthetized with 5 ml per kg of body weight of 0.2 ml ketamine (Fort Dodge), 0.1 ml xylazine (Lloyd Laboratories) and 0.7 ml of distilled water. After shaving and cleaning with ethanol and betadine, a T10 laminectomy was performed in a 0.05. Statistical analysis was performed on the results on a number of genes apparently exhibiting differential expression. Pre-normalized data were then filtered by volcano plot to identify genes whose expression ratio for every gene in each of the control groups was calculated from the outer perimeter of the axon divided by the total perimeter of the axon and myelin. Six genes of interest Assay ID Common Name

| Genes of interest | Assay ID* | Common Name          |
|-------------------|----------|----------------------|
| IL-17a            | Mm00439619.m1 | interleukin 17A       |
| NOS-2             | Mm01309092.m1 | Nitric oxide synthase 2 |
| IFN-γ             | Mm99999071.m1 | hemeoxgenase 1         |
| HMox1             | Mm00516007.m1 | interferon gamma        |
| NF-2              | Mm03053465_s1 | nuclear receptor subfamily 2, group F, member 2 |
| Pgdgs             | Mm01330614.g1 | PDG2; PDGS              |
| Grin3b            | Mm00504568.m1 | NRG3B                  |
| Star2             | Mm00490880.m1 | AW496480               |
| Cd68              | Mm00839636.g1 | gp110; Scard1           |
| Csf3r             | Mm00432735.m1 | Cdl14; Csfgr, G-CSFR    |
| Tgfbr1            | Mm00436971.m1 | ALKS; Alk-5; TbetaRI    |
| Hsd11b1           | Mm00476182.m1 | Hsd11b1                |
| Cd74              | Mm00658576.m1 | li; CLIP; DHLAG         |
| Cd84              | Mm00488934.m1 | CDw84; SLAMF5           |
| β-Actin           | Mm00670399.s1 |                       |

1. Noseworthy, J. H., Luchinetti, C., Rodrigo, M. & Weinschenker, B. G. Multiple sclerosis. *N Engl J Med* **343**, 938–952 (2000).
2. Gutcher, L. et al. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. *Immunity* **34**, 396–408 (2011).
3. Benveniste, E. N. Cytokine actions in the central nervous system. *Cytokine Growth Factor Rev* **9**, 259–275 (1998).
4. Rauls, S. R., et al. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. *J Neuroimmunol* **56**, 207–217 (1995).
5. Gilgun-Sherki, Y., Melled, E. & Offen, D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. *J Neurosci** **25**, 261–268 (2004).
6. Smith, K. J., Kapoor, R. & Felts, P. A. Demyelination: the role of reactive oxygen and nitrogen species. *Brain Pathol** **9**, 69–92 (1999).
7. van Meeteren, M. E., Teunissen, C. E., Dijkstra, C. D. & van Tol, E. A. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. *Eur J Clin Nutr** **59**, 1347–1361 (2005).
8. Johnson, D. A., Amirahmadi, S., Ward, C., Fabry, Z. & Johnson, J. A. The absence of the pro-antioxidant transcription factor Nr22 exacerbates experimental autoimmune encephalomyelitis. *Toxicol Sci* **114**, 237–246 (2010).
9. Innamorato, N. G., et al. The transcription factor Nr22 is a therapeutic target against brain inflammation. *J Immunol** **181**, 680–689 (2008).
10. Hubbs, A. F., et al. Vascular leukoencephalopathy with widespread astroglisis in mice lacking transcription factor Nr22. *Am J Pathol** **170**, 2068–2076 (2007).
11. Tajouri, L., et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. *Brain Res Mol Brain Res** **119**, 170–183 (2003).
12. Guy, J., Qi, X. & Hauswirth, W. W. Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. *Proc Natl Acad Sci U S A* **95**, 18384–18382 (1998).
13. Singh, L. et al. Unpaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. *Brain Res** **1022**, 1–11 (2004).
14. Liu, Y., Liu, J., Tetzlaff, W., Patty, D. W. & Cynader, M. S. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. *Free Radic Biol Med** **40**, 960–967 (2006).
15. Liu, Y., et al. Heme oxgenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. *Neuroreport** **12**, 1841–1845 (2001).
16. Connolly, J. D. & Hill, R. A. Triterpenoids. *Nat Prod Rep** **18**, 560–570 (2001).
17. Xu, R., Fazio, G. C. & Matsuda, S. P. On the origins of triterpenoid skeletal diversity. *Phytochemistry** **65**, 261–291 (2004).
18. Dzubak, P., et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. *Nat Prod Rep** **23**, 394–411 (2006).
19. Liu, J. Oleandonic acid and ursolic acid: research perspectives. *J Ethnopharmacol** **100**, 92–94 (2005).
20. Bghrad, T. J. & Kuttan, G. Effect of naturally occurring triterpenoids glycyrrhizic acid, ursolic acid, oleanolic acid and nosinol on the immune system. Phytotherapy 10, 483–489 (2003).
21. Martin, R., et al. Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: a potential therapeutic role. Biochem Pharmacol 79, 198–208 (2010).
22. Tran, T. A., McCoy, M. K., Sporn, M. B. & Tansey, M. G. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation 5, 14 (2008).
23. Pergola, P. E., et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3–4 CKD. Am J Nephrol 33, 469–476 (2011).
24. Pergola, P. E., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365, 327–336 (2011).
25. Dumont, M., et al. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease. J Neurochem 109, 502–512 (2009).
26. Liby, K. T., Yore, M. M. & Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7, 357–369 (2007).
27. Stack, C., et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluorooethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic Biol Med 49, 147–158 (2010).
28. Liby, K., et al. The synthetic triterpenoid CDDO-Izomalidazole suppresses STAT phosphorylation and reduces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12, 4288–4293 (2006).
29. Yore, M. M., Liby, K. T., Honda, T., Gribble, G. W. & Sporn, M. B. The synthetic triterpenoid 1-[2-cyano-3,12-dioxoloena-1,9-(11)-di-en-28-oyl]izomalidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther 5, 3232–3239 (2006).
30. Bayer, A. L., Lee, J. Y., de la Barrera, A., Surh, C. D. & Malek, T. R. A function for IL-7R for CD4 memory T cells. Proc Natl Acad Sci U S A 104, 3024–3027 (1993).
31. Lin, R. F., Lin, T. S., Tilton, R. G. & Cross, A. H. Nitric oxide localized to spinal cord lesions. Proc Natl Acad Sci U S A 90, 198–201 (1993).
32. Lin, R. F., et al. Triterpenoids CDDO-ethylamide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic Biol Med 49, 147–158 (2010).
33. Okuda, Y., et al. Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin Exp Immunol 162, 210–223 (2010).
34. Heidbrink, C., et al. Reduced cortical levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis. Brain Behav Immun 24, 975–984 (2010).
35. Huang, Y. C., et al. Decreased intrathecal synthesis of prostaglandin D2 synthase in the cerebrospinal fluid of patients with acute inflammatory demyelinating polyneuropathy. J Neuroinflammation 206, 100–105 (2009).
36. Rajakariar, R., et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A 104, 20979–20984 (2007).
37. Ikeda, Y., et al. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NR2F. J Biol Chem 275, 33142–33150 (2000).
38. Gold, R., Linker, R. A. & Stangel, M. Fumicar acid and its esters: An emerging treatment for multiple sclerosis with antioxidant mechanism of action. Clin Immunol (2011).
39. Linker, R. A., et al. Fumicaric acid esters exert neuroprotective effects in neuroinflammation via activation of the NRf2 antioxidant pathway. Brain 134, 678–692 (2011).

Acknowledgments
We are thankful to Janet Robinson and Jennifer Alabran for their expert technical support and helpful discussions. We also thank NUS, Singapore for providing travel support for Dr. Pareek. This work was supported by the intramural funds from CRWU and The Case Research Institute. Dr. Letterio would like to thank Jane and Lee Seidman for their support through their endowment for Pediatric Cancer Innovation.

Authors contribution
J.J.L and T.K.P. conceived and coordinated the study, designed the experiments, analyzed the data and wrote the manuscript. T.K.P. carried out major biochemical and biological experiments, M.L.C. performed histopathological analyses, C.M., K.T.L., R.H.M., L.B. helped with microarray experiments, A.Z. carried out OPC maturation experiments, S.K. and S.L.L. performed and analyzed the data and wrote the manuscript, T.K.P. carried out major biochemical and biological experiments, A.B carried out LPC studies, S.K. and S.L.L. performed and analyzed the data and wrote the manuscript.

Additional information
Supplementary information accompanies this paper at http://www.nature.com/scientificreports